SLC25A22 and neoplasm: 4) Furthermore, to explore the therapeutic value of targeting SLC25A22, we constructed 3D CSCC organoids that retained the morphological and genomic features of parental tumors and developed an innovative 3D T‐cell‐incorporated CSCC organoid models mimicking the interaction between tumor cells and T cells.